ClinicalTrials.gg
WithdrawnNCT05441930Updated Apr 12, 2024

A Study of Levofloxacin Ocular Implant in Patients Undergoing Routine Bilateral Cataract Surgery

A Phase 1 interventional study of Levofloxacin Ocular Implant and Control in Cataract, sponsored by PolyActiva Pty Ltd. Withdrawn at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-12.

Sponsored by PolyActiva Pty Ltd · Phase 1, Interventional, and Treatment

How we know

Why this study was withdrawn
Sponsor has suspended study to conserve capital for clinical development of lead asset

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 456 studies in Cataract with a site in United States — 49 open to participants now, 56 under way, 4 of them phase 3. Cataract · United States.

Enrollment
310th of 322
0 · median 100
Started
2023
with 27 others
Phase 1
10 of 456
1 open now
Registered
340th of 456
by date

Among the 456 studies in Cataract with a site in United States, this one is the 310th largest by enrollment of the 322 interventional ones that give a count, is one of 28 that started in 2023, is one of 10 in phase 1, and was the 340th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

49 of the 456 studies in Cataract with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 456 studies in Cataract with a site in United States, or all of them as a file.
02

Study summary

Open label controlled interventional study in eyes in up to 12 subjects (24 eyes) scheduled for uncomplicated bilateral cataract surgery on separate days.

Read the detailed description

This is a multicenter, open label, controlled, pairwise, interventional study in eyes in up to 12 subjects (24 eyes) scheduled for uncomplicated bilateral cataract surgery on separate days. Eligible individuals provide informed consent; and are screened for inclusion in the study.

Once eligible, subject eyes will be randomized to determine which eye will receive the first surgery. After the first surgery, study participants will receive the control treatment consisting of commercially available topical medications. For the second cataract surgery, study participants will receive a single Levofloxacin Ocular Implant in the posterior sulcus in the surgical eye at the end of cataract surgery. No sham dosing will be conducted in the eyes in the control arm.

03

Conditions studied

  • Cataract

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  1. Male or female subjects 18 years of age or older.
  2. Willing and able to understand and sign an form prior to any study-related procedures.
  3. Willing and able to follow study instructions, and able to be present for the required study visits/assessments for the duration of the study.
  4. Diagnosis of cataract in both eyes scheduled for sequential bilateral elective cataract extraction by phacoemulsification and posterior chamber IOL implantation not combined with any other surgery except femtosecond laser.
  5. Minimum endothelial cell density (ECD) in both eyes of greater than or equal to 2000 cells per mm2.
  6. Fully vaccinated against COVID-19, as evidenced by vaccination record.

Key Opthalmic Exclusion Criteria

Ophthalmic:

  1. Have a history of or current uveitis, macular edema (cystoid or diabetic), diabetic retinopathy, retinal vein occlusion and neovascular glaucoma, corneal conditions such as keratitis, corneal edema or advanced macular degeneration, which in the opinion of the investigator would interfere with study assessments and confound the data.
  2. In the opinion of the investigator or reading center, have confluent central corneal guttatae, multiple central guttatae greater than a single cell, or corneal disease or abnormality that would prevent specular microscopy corneal scans.
  3. Aphakia or low vision or monocular.
  4. Have had any intraocular surgery, glaucoma surgery (including but not limited to filtering surgery like trabeculectomy, Ahmed valve, etc) or cornea/refractive surgery within the past 6 months or anticipate a need for eye surgery (including laser) during the study period.
  5. Use of prostaglandin (PG) analogues within 60 days prior to Screening or during the course of the study.
  6. Subjects with clinically diagnosed Fuchs' Endothelial Corneal Dystrophy (FECD)/ history of keratoplasty.
  7. Subjects for whom an intra-ocular or glaucoma device procedure is planned during the cataract procedure, during study participation or has been previously undertaken.
  8. Have a current retinal detachment or history of blunt trauma in either eye.
  9. Subject who in the opinion of the surgeon has a high risk of the posterior capsule being compromised/zonular dehiscence during cataract surgery.
  10. Intraoperative complications during the cataract surgery including posterior capsule rupture, zonular dehiscence, non-placement of Posterior Chamber Intra Ocular Lens (PCIOL), vitreous prolapse, lens fragments in the vitreous, placement of Anterior Chamber Intra Ocular Lens (ACIOL), uncontrolled bleeding /hyphema.
  11. Known sensitivity to any component of the product (e.g. fluoroquinolone or polyurethane sensitivity), or to topical therapy used during course of study (e.g., povidone iodine, or anesthetics).
  12. Used fluoroquinolone antibiotics (topically, orally or systemically) during the 4 weeks before screening visit.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Levofloxacin Ocular Implant

    Biphasic levofloxacin antibiotic implant

    Drug: Levofloxacin Ocular Implant

  • Active comparator
    Control

    Commercially available topical medications as per LEVO-CS102 Surgical Therapy Procedure.

    Drug: Control

Interventions

  • DrugLevofloxacin Ocular Implant

    Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.

  • DrugControl

    Commercially available topical medications as per LEVO-CS102 Surgical Therapy Procedure.

06

What researchers measure

Primary outcomes

  1. Safety of the Levofloxacin Ocular Implant

    Descriptive summary statistics will be used to assess the number and frequency of ocular and non ocular adverse events

    Time frame: Day 90

  2. Levofloxacin concentration in aqueous humor at Day 5 in treated eyes

    To determine levofloxacin concentration in aqueous humor at Day 5 in eyes with the Levofloxacin Ocular Implant to facilitate dose adjustment for Phase II studies.

    Time frame: Day 5

Secondary outcomes

  1. Number of actuations required to administer the implant

    Clinicians administering the implant will record the number of actuations required to use the custom-built administration device

    Time frame: Day 0

07

Study locations

3 sites
  • Ophthalmology Associates
    Saint Louis, Missouri 63131, United States
  • Carolina Cataract and Laser Centre
    Ladson, South Carolina 29456, United States
  • Melbourne Eye Specialists
    Fitzroy, Victoria 3065, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2023; primary completion for Dec 2023, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2022
First posted
Jul 1, 2022
StartEst.
Jun 23, 2023
Primary completionEst.
Dec 15, 2023
CompletionEst.
Mar 14, 2024
Last update
Apr 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05441930
Lead sponsor
PolyActiva Pty Ltd
Responsible party
Sponsor
First posted
Jul 1, 2022
Start date
Jun 23, 2023 (estimated)
Primary completion
Dec 15, 2023 (estimated)
Completion
Mar 14, 2024 (estimated)
Last update
Apr 12, 2024

Study contacts

Michael Coote, MD
principal investigator · Melbourne Eye Specialists

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion